FINWIRES · TerminalLIVE
FINWIRES

Raytron Technology to Cancel Nearly 5 Million Repurchased Shares; Shares Rise 9%

By

Raytron Technology (SHA:688002) will cancel nearly 5 million shares it repurchased through a share buyback program, according to a Friday bourse filing in Shanghai.

The shares were supposed to be allocated for employee stock ownership plans.

Upon cancellation, Raytron's shareholding will reduce to 460.8 million shares from 465.7 million shares.

Raytron attributed the change in purpose of the repurchased but unused shares to "convey company value and enhance investor confidence."

Shares rose 9% during late afternoon trading on Friday.

Related Articles

Asia

SEEK Can 'Easily Achieve' Fiscal Year 2026 Yield Growth Guidance, Says Jarden

SEEK (ASX:SEK) could "easily achieve" its low double-digit yield growth guidance for fiscal year 2026 and is expected to grow by 13.5%, according to a Thursday note by Jarden.Jarden has updated its forecast for the fiscal year 2027 Australia-New Zealand business yield growth to 9% from 8.5%, but offset by its downgrade to the fiscal year 2027 volume assumption to negative 2.5% from flat.The research firm believes that the Australian labor market is past its peak, and currently expects the Australian unemployment rate to increase to 4.8% by June 2027, which is currently at 4.5%, resulting in a reduction to its assumption.Jarden maintained a buy rating on Seek and reduced its price target to AU$23.25 from AU$23.50.

$ASX:SEK
Asia

Market Chatter: Lendlease Group Asks KPMG to Remove ASIC Probe-Associated Staff From Its Accounts, The Australian Reports

Lendlease Group (ASX:LLC) asked KPMG to remove all staff who are the subject of the Australian Securities & Investments Commission's probe arising from the accounting firm's audit scandal from its accounts, according to a Friday report by The Australian.Lendlease sought a guarantee from the auditing firm "that no employees currently on our audit have been, or are, the subject of any investigations," the report said, citing a company spokeswoman.In March, Australian Senator Deborah O'Neill revealed a whistleblower's allegations of misconduct at KPMG, including confidential papers from Lendlease that were allegedly used to support bids for major audit tenders for Westpac and Dexus, according to a Reuters report.Lendlease did not immediately respond to' request for comment.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

$ASX:LLC
Asia

Zhaoke Ophthalmology Grants Commercialization Licence for Dry Eye Drug in Indonesia

Zhaoke Ophthalmology (HKG:6622) entered into a distribution and supply agreement with Erlangga Edi Laboratories to commercialize CsA Ophthalmic Gel in Indonesia, according to a Friday Hong Kong bourse filing.Under the agreement, the ophthalmic drug maker granted Erlangga exclusive rights to register, import, promote, distribute, market, and sell the dry eye disease drug in Indonesia.The firm will receive an upfront payment and additional milestone payments based on specific achievements.

$HKG:6622